Streetbeat News

Analyst Ratings

FDMT

Cantor Fitzgerald analyst Josh Schimmer has reiterated an Overweight rating on 4D Molecular Therapeutics (NASDAQ:FDMT).

Portfolio Pulse from Benzinga Newsdesk

September 09, 2024 | 5:03 pm

EOLS

Cantor Fitzgerald analyst Louise Chen has reiterated an Overweight rating on Evolus (NASDAQ:EOLS).

Portfolio Pulse from Benzinga Newsdesk

September 09, 2024 | 5:01 pm

CI

Over the past three months, 8 analysts have evaluated Cigna (NYSE:CI), with all ratings being somewhat bullish. The average 12-month price target is $404.62, showing a slight increase from previous estimates. Cigna's financial health is strong, with notable revenue growth and effective debt management, though its net margin lags behind industry averages.

Portfolio Pulse from Benzinga Insights

September 09, 2024 | 5:01 pm

KR

Kroger (NYSE:KR) has received mixed analyst ratings, with a majority being somewhat bullish. The average 12-month price target is $61.62, with a high of $72.00 and a low of $57.00. Analysts have adjusted their ratings and price targets based on market dynamics and company performance. Kroger's financials show positive revenue growth, strong net margin, and efficient asset management, despite a lower growth rate compared to peers.

Portfolio Pulse from Benzinga Insights

September 09, 2024 | 5:01 pm

HURN

In the past three months, four analysts have evaluated Huron Consulting Group (NASDAQ:HURN), with ratings ranging from bullish to somewhat bullish. The average 12-month price target is $138.5, reflecting a slight increase from previous estimates. Analysts maintain positive ratings, with Barrington Research and Benchmark providing 'Outperform' and 'Buy' ratings, respectively. Huron Consulting's financial health is strong, with impressive net margins and return on equity, despite facing growth challenges compared to industry peers.

Portfolio Pulse from Benzinga Insights

September 09, 2024 | 5:01 pm

CYTK

Cantor Fitzgerald analyst Charles Duncan has reiterated an Overweight rating on Cytokinetics (NASDAQ:CYTK).

Portfolio Pulse from Benzinga Newsdesk

September 09, 2024 | 5:00 pm

NVO

Novo Nordisk (NYSE:NVO) has received 8 'Somewhat Bullish' ratings from analysts in the past three months, with an average 12-month price target of $160.38, slightly down from $161.62. Analysts maintain positive outlooks despite a slight decrease in price targets. Novo Nordisk shows strong financial performance with significant revenue growth, high net margins, and efficient asset management.

Portfolio Pulse from Benzinga Insights

September 09, 2024 | 5:00 pm

CLDX

Analysts have mixed ratings for Celldex Therapeutics (NASDAQ:CLDX), with a range of bullish to bearish sentiments. The average 12-month price target is $68.29, slightly up from the previous $68.00. The company has shown significant revenue growth but struggles with profitability and asset returns.

Portfolio Pulse from Benzinga Insights

September 09, 2024 | 5:00 pm

YMAB

Y-mAbs Therapeutics (NASDAQ:YMAB) received mixed analyst ratings, with a slight downward trend in price targets. The company shows strong financial metrics but lags in revenue growth compared to peers.

Portfolio Pulse from Benzinga Insights

September 09, 2024 | 5:00 pm

CMPS

Cantor Fitzgerald analyst Charles Duncan has reiterated an Overweight rating on Compass Pathways (NASDAQ:CMPS).

Portfolio Pulse from Benzinga Newsdesk

September 09, 2024 | 4:59 pm